Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion

Cancer Genomics and Proteomics

Volumn 12, Issue 2, 2015, Pages 89-101

  Milioli, Heloisa Helena ^a   Sousa, Karla Santos ^a   Kaviski, Rodrigo ^a   Oliveira, Nayara Cristina Dos Santos ^a   De Andrade Urban, Cícero ^b   De Lima, Rubens Silveira ^a,b   Cavalli, Iglenir João ^a   De Souza Fonseca Ribeiro, Enilze Maria ^a,c  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b HOSPITAL NOSSA SENHORA DAS GRAÇAS   (Brazil)

^c UNIVERSIDADE TECNOLÓGICA FEDERAL DO PARANÁ   (Brazil)

Author keywords

2D PAGE; Breast cancer; Lymph node; MALDI ToF; Markers; Mass spectrometry; Metastasis; Proteomics; Tumour invasion

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 2; ALPHA 1 ANTITRYPSIN; ALPHA SOLUBLE NSF ATTACHMENT PROTEIN; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CYTOSOL AMINOPEPTIDASE; ELONGATION FACTOR TS; FERRITIN LIGHT CHAIN; FIBRINOGEN BETA CHAIN; HEAT SHOCK PROTEIN BETA 1; INTERLEUKIN 6; KERATIN TYPE I CYTOSKELETAL 19; KERATIN TYPE I CYTOSKELETAL 8; LIPOCORTIN 1; MICROTUBULE ACTIN CROSS LINKING FACTOR 1; MITOCHONDRIAL ENDOPLASMIN; NEURON SPECIFIC ENOLASE; PEROXIREDOXIN 1; PROHIBITIN; PROTEASOME ACTIVATOR COMPLEX SUBUNIT 2; PROTEIN; PROTEIN 14 3 3 GAMMA; PROTEIN 14 3 3 THETA; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 2; RIBOSOMAL RNA PROCESSING PROTEIN 1 HOMOLOG A; RING FINGER PROTEIN 213; SEROTRANSFERRIN; TROPOMYOSIN ALPHA 4 CHAIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIMENTIN; PROTEOME; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER PROGNOSIS; CANCER RESEARCH; CELL FATE; CELL FUNCTION; CELL INTERACTION; CELL JUNCTION; CELL MEMBRANE; CELLULAR STRESS RESPONSE; CLINICAL ARTICLE; CYTOPLASM; CYTOSKELETON; ENDOPLASMIC RETICULUM; ENDOSOME; EXTRACELLULAR MATRIX; FEMALE; GOLGI COMPLEX; HUMAN; INTERMEDIATE FILAMENT; LYMPH NODE METASTASIS; MASS SPECTROMETRY; MIDDLE AGED; PRIMARY BREAST TUMOR; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TUMOR INVASION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; COMPARATIVE STUDY; METABOLISM; PATHOLOGY;

AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTEOME; PROTEOMICS; UP-REGULATION;

EID: 84925252801     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Goncalves A, Charafe-Jauffret E, Bertucci F, Audebert S, Toiron Y, Esterni B, Monville F, Tarpin C, Jacquemier J, Houvenaeghel G, Chabannon C, Extra J, Viens P, Borg J and Birnbaumf D: Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes. Mol Cell Proteomics 7: 1420-1433, 2008.
2. Stacker SA, Achen MG, Jussila L, Baldwin ME and Alitalo K: Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2: 573-583, 2002.
3. Ran S, Volk L, Hall K and Flister MJ: Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiol 17: 229-251, 2010.
4. Cunnick GH, Jiang WG, Douglas-Jones T, Watkins G, Gomez KF, Morgan MJ, Subramanian A, Mokbel K and Mansel RE: Lymphangiogenesis and lymph node metastasis in breast cancer. Mol Cancer 7: 23, 2008.
5. Wood SL, Westbrook JA and Brown JE: Omic-profiling in breast cancer metastasis to bone: implications for mechanisms, biomarkers and treatment. Cancer Treat Rev 40: 139-152, 2014.
6. Ho J, Kong J, Choong L, Loh M, Toy W, Chong P, Wong C, Wong C, Shah N and Lim Y: Novel Breast Cancer Metastasis-Associated Proteins. J Proteome Res 8: 583-594, 2009.
7. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL and van't Veer LJ: Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 100: 15901-15905, 2003.
8. Weigelt B, Wessels LF, Bosma AJ, Glas AM, Nuyten DS, He YD, Dai H, Peterse JL and van't Veer LJ: No common denominator for breast cancer lymph node metastasis. Br J Cancer 93: 924-932, 2005.
9. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ and Consortium T: The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116: 295-302, 2009.
10. Jacobs LK and Balch CM: Predicting the Risk of Axillary Nodal Metastases. J Clin Oncol 27: 1-3, 2009.
11. Natarajan S, Taneja C and Cady B: Evolution of Lymphadenectomy in Surgical Oncology. Surg Oncol Clin N Am 14: 447-459, 2005.
12. Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, Winchester DP and Winchester DJ: Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 27: 2946-2953, 2009.
13. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP and American Society of Clinical O: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23: 7703-7720, 2005.
14. Nakagawa T, Huang SK, Martinez SR, Tran AN, Elashoff D, Ye X, Turner RR, Giuliano AE and Hoon DS: Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. Cancer Res 66: 11825-11830, 2006.
15. Suzuki M and Tarin D: Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: clinical implications. Mol Oncol 1: 172-180, 2007.
16. Feng Y, Sun B, Li X, Zhang L, Niu Y, Xiao C, Ning L, Fang Z, Wang Y, Zhang L, Cheng J, Zhang W and Hao X: Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat 103: 319-329, 2007.
17. Santos SC, Cavalli IJ, Ribeiro EM, Urban CA, Lima RS, Bleggi-Torres LF, Rone JD, Haddad BR and Cavalli LR: Patterns of DNA copy number changes in sentinel lymph node breast cancer metastases. Cytogenet Genome Res 122: 16-21, 2008.
18. Li J, Gromov P, Gromova I, Moreira JM, Timmermans-Wielenga V, Rank F, Wang K, Li S, Li H, Wiuf C, Yang H, Zhang X, Bolund L and Celis JE: Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis. Proteomics 8: 5038-5052, 2008.
19. Hu X, Zhang Y, Zhang A, Li Y, Zhu Z, Shao Z, Zeng R and Xu LX: Comparative Serum Proteome Analysis of Human Lymph Node NegativePositive Invasive Ductal Carcinoma. OMICS 13: 1-10, 2009.
20. Thongwatchara P, Promwikorn W, Srisomsap C, Chokchaichamnankit D, Boonyaphiphat P and Thongsuksai P: Differential protein expression in primary breast cancer and matched axillary node metastasis. Oncol Rep 26: 185-191, 2011.
21. Bradford MM: A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Anal Biochem 72: 248-254, 1976.
22. Dupont A, Corseaux D, Dekeyzer O, Drobecq H, Guihot A-L, Susen S, Vincentelli A, Amouyel P, Jude B and Pinet F: The proteome and secretome of human arterial smooth muscle cells. Proteomics 5: 585-596, 2005.
23. Graves PR and Haystead TAJ: Molecular Biologist's Guide to Proteomics. Microbiol Mol Biol Rev 66: 39-63, 2002.
24. Pucci-Minafra I, Cancemi P, Fontana S, Minafra L, Feo S, Becchi M, Freyria AM and Minafra S: Expanding the protein catalogue in the proteome reference map of human breast cancer cells. Proteomics 6: 2609-2625, 2006.
25. Pucci-Minafra I, Cancemi P, Marabeti MR, Albanese NN, Di Cara G, Taormina P and Marrazzo A: Proteomic profiling of 13 paired ductal infiltrating breast carcinomas and non-tumoral adjacent counterparts. Proteomics Clin Appl 1: 118-129, 2007.
26. Vercoutter-Edouart A, Lemoine J, Le Bourhis X, Louis H, Boilly B, Nurcombe V, Revillion F, Peyrat J and Hondermarck H: Proteomic Analysis Reveals that 14-3-3σ Is Down-Regulated in Human Breast Cancer Cells. Cancer Res 61: 76-80, 2001.
27. Alexander H, Stegner AL, Wagner-Mann C, Alexander S, Du Bois GC and Sauter ER: Proteomic Analysis to Identify Breast Cancer Biomarkers in Nipple Aspirate Fluid. Clin Cancer Res 10: 7500-7510, 2004.
28. Al-Ghoul M, Bruck TB, Lauer-Fields JL, Asirvatham VS, Zapata C, Kerr RG and Fields GB: Comparative Proteomic Analysis of Matched Primary and Metastatic Melanoma Cell Lines. J Proteome Res 7: 4107-4118, 2008.
29. Bertucci F, Birnbaum D and Goncalves A: Proteomics of Breast Cancer - Review. Mol Cell Proteomics 5: 1772-1786, 2006.
30. Hondermarck H, Tastet C, El Yazidi-Belkoura I, Toillon RA and Le Bourhis X: Proteomics of breast cancer: the quest for markers and therapeutic targets. J Proteome Res 7: 1403-1411, 2008.
31. Vydra J, Selicharova I, Smutna K, Sanda M, Matouskova E, Bursikova E, Prchalova M, Velenska Z, Coufal D and Jiracek J: Two-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues. BMC Cancer 8: 107, 2008.
32. Jiang N, Kham SK, Koh GS, Suang Lim JY, Ariffin H, Chew FT and Yeoh AE: Identification of prognostic protein biomarkers in childhood acute lymphoblastic leukemia (ALL). J Proteomics 74: 843-857, 2011.
33. Huang Q, Huang Q, Lin W, Lin J and Lin X: Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis. J Cancer Res Clin Oncol 136: 1275-1282, 2010.
34. Kim JE, Koo KH, Kim YH, Sohn J and Park YG: Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model. Exp Mol Med 40: 709-720, 2008.
35. Ebert MP, Kruger S, Fogeron ML, Lamer S, Chen J, Pross M, Schulz HU, Lage H, Heim S, Roessner A, Malfertheiner P and Rocken C: Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 5: 1693-1704, 2005.
36. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kultz D and Weiss RH: Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 5: 64, 2006.
37. Andreeva AV, Kutuzov MA and Voyno-Yasenetskaya TA: A ubiquitous membrane fusion protein αSNAP: a potential therapeutic target for cancer, diabetes and neurological disorders? Expert Opin Ther Targets 10: 723-733, 2006.
38. Skirnisdottir I, Bjersand K, Åkerud H and Seidal T: Napsin A as a marker of clear cell ovarian carcinoma. BMC Cancer 13: 524, 2013.
39. Choi C, Kim D, Kim S, Jeong S, Song E and Helfman DM: From skeletal muscle to cancer: insights learned elucidating the function of tropomyosin. J Struct Biol 177: 63-69, 2012.
40. Grenklo S, Hillberg L, Zhao Rathje LS, Pinaev G, Schutt CE and Lindberg U: Tropomyosin assembly intermediates in the control of microfilament system turnover. Eur J Cell Biol 87: 905-920, 2008.
41. Assinder SJ, Au E, Dong Q and Winnick C: A novel splice variant of the beta-tropomyosin (TPM2) gene in prostate cancer. Mol Carcinog 49: 525-531, 2010.
42. Tang HY, Beer LA, Tanyi JL, Zhang R, Liu Q and Speicher DW: Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer. J Proteomics 89: 165-178, 2013.
43. Sahab ZJ, Man YG, Semaan SM, Newcomer RG, Byers SW and Sang QX: Alteration in protein expression in estrogen receptor alpha-negative human breast cancer tissues indicates a malignant and metastatic phenotype. Clin Exp Metastasis 27: 493-503, 2010.
44. Carlsson MC, Bengtson P, Cucak H and Leffler H: Galectin-3 guides intracellular trafficking of some human serotransferrin glycoforms. J Biol Chem 288: 28398-28408, 2013.
45. Kim DH, Bae J, Lee JW, Kim SY, Kim YH, Bae JY, Yi JK, Yu MH, Noh DY and Lee C: Proteomic analysis of breast cancer tissue reveals upregulation of actin-remodeling proteins and its relevance to cancer invasiveness. Proteomics Clin Appl 3: 30-40, 2009.
46. Satelli A and Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68: 3033-3046, 2011.
47. Johann DJ, Rodriguez-Canales J, Mukherjee S, Prieto DA, Hanson JC, Emmert-Buck M and Blonder J: Approaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry. J Proteome Res 8: 2310-2318, 2009.
48. Ulirsch J, Fan C, Knafl G, Wu MJ, Coleman B, Perou CM and Swift-Scanlan T: Vimentin DNA methylation predicts survival in breast cancer. Breast Cancer Res Treat 137: 383-396, 2013.
49. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J: Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30: 1436-1448, 2011.
50. Shao MM, Chan SK, Yu AM, Lam CC, Tsang JY, Lui PC, Law BK, Tan PH and Tse GM: Keratin expression in breast cancers. Virchows Arch 461: 313-322, 2012.
51. Alix-Panabieres C, Vendrell JP, Slijper M, Pelle O, Barbotte E, Mercier G, Jacot W, Fabbro M and Pantel K: Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 11: R39, 2009.
52. Ohi Y, Umekita Y, Sagara Y, Rai Y, Yotsumoto D, Matsukata A, Baba S, Tamada S, Matsuyama Y, Ando M, Sagara Y, Sasaki M, Tsuchimochi S, Tanimoto A and Sagara Y: Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer. Br J Cancer 107: 1239-1243, 2012.
53. Osako T, Iwase T, Kimura K, Horii R and Akiyama F: Sentinel node tumour burden quantified based on cytokeratin 19 mRNA copy number predicts non-sentinel node metastases in breast cancer: molecular whole-node analysis of all removed nodes. Eur J Cancer 49: 1187-1195, 2013.
54. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL and Perez EA: Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res 17: 7183-7193, 2011.
55. Ju JH, Yang W, Lee KM, Oh S, Nam K, Shim S, Shin SY, Gye MC, Chu IS and Shin I: Regulation of cell proliferation and migration by keratin19-induced nuclear import of early growth response-1 in breast cancer cells. Clin Cancer Res 19: 4335-4346, 2013.
56. Skalnikova H, Martinkova J, Hrabakova R, Halada P, Dziechciarkova M, Hajduch M, Gadher SJ, Hammar A, Enetoft D, Ekefjard A, Forsstrom-Olsson O and Kovarova H: Cancer Drug-Resistance and a Look at Specific Proteins: Rho GDP-Dissociation Inhibitor 2, Y-Box Binding Protein 1, and HSP70/90 Organizing Protein in Proteomics Clinical Application. J Proteome Res 10: 404-415, 2010.
57. Moissoglu K, McRoberts KS, Meier JA, Theodorescu D and Schwartz MA: Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res 69: 2838-2844, 2009.
58. Urquidi V and Goodison S: Genomic signatures of breast cancer metastasis. Cytogenet Genome Res 118: 116-129, 2007.
59. Hodgkinson VC, Agarwal V, D EL, Fox JN, McManus PL, Mahapatra TK, Kneeshaw PJ, Drew PJ, Lind MJ and Cawkwell L: Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ERpositive breast cancer. J Proteomics 75: 2745-2752, 2012.
60. Fritz G and Kaina B: Rho GTPases: Promising Cellular Targets for Novel Anticancer Drugs. Curr Cancer Drug Targets 6: 1-4, 2006.
61. Muzio G, Maggiora M, Paiuzzi E, Oraldi M and Canuto RA: Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med 52: 735-746, 2012.
62. Shaheed SU, Rustogi N, Scally A, Wilson J, Thygesen H, Loizidou MA, Hadjisavvas A, Hanby A, Speirs V, Loadman P, Linforth R, Kyriacou K and Sutton CW: Identification of stage-specific breast markers using quantitative proteomics. J Proteome Res 12: 5696-5708, 2013.
63. Sutton CW, Rustogi N, Gurkan C, Scally A, Loizidou MA, Hadjisavvas A and Kyriacou K: Quantitative Proteomic Profiling of Matched Normal and Tumor Breast Tissues. J Proteome Res 9: 3891-3902, 2010.
64. Song BJ, Abdelmegeed MA, Yoo SH, Kim BJ, Jo SA, Jo I and Moon KH: Post-translational modifications of mitochondrial aldehyde dehydrogenase and biomedical implications. J Proteomics 74 : 2691-2702, 2011.
65. Ou K, Yu K, Kesuma D, Hooi M, Huang N, Chen W, Lee SY, Goh XP, Tan LK, Liu J, Soon SY, Rashid SBA, Putti TC, Jikuya H, Ichikawa T, Nishimura O, Salto-Tellez M and Tan P: Novel Breast Cancer Biomarkers Identified by Integrative Proteomic and Gene Expression Mapping. J Proteome Res 7: 1518-1528, 2008.
66. Kruger S, Elmageed ZY, Hawke DH, Wörner PM, Jansen DA, Abdel-Mageed AB, Alt EU and Izadpanah R: Molecular characterization of exosome-like vesicles from breast cancer cells. BMC Cancer 14: 44, 2014.
67. Zaretsky JZ and Wreschner DH: Protein Multifunctionality. Principles and Mechanisms. Transl Oncogenomics 3: 99-136, 2008.
68. Mellman I and Nelson WJ: Coordinated protein sorting, targeting and distribution in polarized cells. Nat Rev Mol Cell Biol 9: 833-845, 2008.
69. Polyak K and Kalluri R: The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2: a003244, 2010.
70. Deng S-S, Xing T-Y, Zhou H-Y, Xiong R-H, Lu Y-G, Wen B, Liu S-Q and Yang H-J: Comparative Proteome Analysis of Breast Cancer and Adjacent Normal Breast Tissues in Human. Genomics Proteomics Bioinformatics 4: 165-172, 2006.
71. Sanders ME, Dias EC, Xu BJ, Mobley JA, Billheimer D, Roder H, Grigorieva J, Dowsett M, Arteaga CL and Caprioli RM: Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. J Proteome Res 7: 1500-1507, 2008.
72. Vecchi M, Confalonieri S, Nuciforo P, Vigano MA, Capra M, Bianchi M, Nicosia D, Bianchi F, Galimberti V, Viale G, Palermo G, Riccardi A, Campanini R, Daidone MG, Pierotti MA, Pece S and Di Fiore PP: Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 27: 2148-2158, 2008.
73. Somiari RI, Somiari S, Russell S and Shriver CD: Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 815: 215-225, 2005.
74. Latterich M, Abramovitz M and Leyland-Jones B: Proteomics: new technologies and clinical applications. Eur J Cancer 44: 2737-2741, 2008.
75. Srinivas PR, Verma M, Zhao Y and Srivastava S: Proteomics for cancer biomarker discovery. Clin Chem 48: 1160-1169 2002.
76. Gast MC, Schellens JH and Beijnen JH: Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat 116: 17-29, 2009.